Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer

被引：10

作者：

Reckamp, Karen L. ^{[1
,2
]}

机构：

[1] City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA 91010 USA

[2] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA

来源：

CANCER LETTERS | 2012年 / 321卷 / 02期

关键词：

Angiogenesis; Non-small cell lung cancer; Tyrosine kinase inhibitor; Vascular disrupting agent; Second-line therapy; PHASE-III TRIAL; TRIPLE ANGIOKINASE INHIBITOR; DOUBLE-BLIND; KINASE INHIBITORS; ENDOTHELIAL-CELLS; 1ST-LINE THERAPY; BEVACIZUMAB; TUMOR; VEGF; SUNITINIB;

D O I：

10.1016/j.canlet.2012.01.041

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

With the approval of the antiangiogenic antibody bevacizumab in non-small cell lung cancer (NSCLC) and other malignancies, the tumor vasculature has emerged as a worthwhile therapeutic target. Second-line therapies have the potential to improve overall survival and quality of life over best supportive care alone. Accordingly, phase II and phase III studies are actively evaluating antiangiogenic treatments in the second-line setting in NSCLC, and results are awaited. Such therapies include antiangiogenic antibodies, small molecule inhibitors, and vascular-disrupting agents. This review will present the current landscape of angiogenesis inhibition in NSCLC, focusing on use as second-line therapy. (c) 2012 Elsevier Ireland Ltd. All rights reserved.

引用

页码：101 / 109

页数：9

共 50 条

[41] Pharmacoeconomic analysis of erlotinib as second-line treatment of advanced non-small cell lung cancer in Taiwan
Hsia, T.
Chang, G.
Chen, Y.
Lin, M.
Su, W.
Tsai, C.
Tsai, C.
Yang, L.
[J]. EJC SUPPLEMENTS, 2007, 5 (04): : 375 - 375
[42] From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?
Ettore D’Argento
Sabrina Rossi
Giovanni Schinzari
Antonia Strippoli
Michele Basso
Alessandra Cassano
Carlo Barone
[J]. Current Treatment Options in Oncology, 2016, 17
[43] From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?
D'Argento, Ettore
Rossi, Sabrina
Schinzari, Giovanni
Strippoli, Antonia
Basso, Michele
Cassano, Alessandra
Barone, Carlo
[J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (12)
[44] Gemcitabine Plus Paclitaxel as Second-line Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
Baykara, Meltem
Coskun, Ugur
Berk, Veli
Ozkan, Metin
Kaplan, Muhammet Ali
Benekli, Mustafa
Karaca, Halit
Inanc, Mevlude
Isikdogan, Abdurrahman
Sevinc, Alper
Elkiran, Emin Tamer
Demirci, Umut
Buyukberber, Suleyman
[J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (10) : 5119 - 5124
[45] Geographic variation in the second-line treatment of non-small cell lung cancer
Edelman, MJ
Sekine, I
Tamura, T
Saijo, N
[J]. SEMINARS IN ONCOLOGY, 2006, 33 (01) : S39 - S44
[46] An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer
Scagliotti, G
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (16) : 2855 - 2866
[47] The safety of second-line treatment options for non-small cell lung cancer
Rossi, Antonio
Maione, Paolo
Santabarbara, Giuseppe
Sacco, Paola Claudia
Casaluce, Francesca
Sgambato, Assunta
Barzelloni, Maria Luisa
Palazzolo, Giovanni
Gridelli, Cesare
[J]. EXPERT OPINION ON DRUG SAFETY, 2017, 16 (04) : 471 - 479
[48] Docetaxel and carboplatin as the second-line treatment of non-small cell lung cancer
Pesek, M
Holá, V
[J]. LUNG CANCER: CURRENT TOPICS, 2001, : 155 - 160
[49] Racotumomab in Non-Small Cell Lung Cancer as Maintenance and Second-Line Treatment
Caceres-Lavernia, Haslen H.
Neninger-Vinageras, Elia
Varona-Rodriguez, Leslie M.
Olivares-Romero, Yoli A.
Sanchez-Rojas, Irlis
Mazorra-Herrera, Zaima
Basanta-Bergolla, Denenke
Duvergel-Calderin, Dayanis
Torres-Cuevas, Boris L.
del Castillo-Carrillo, Concepcion
[J]. MEDICC REVIEW, 2021, 23 (3-4) : 21 - 28
[50] Antiangiogenic treatments of advanced non-small cell lung cancer
Christian Manegold
[J]. Targeted Oncology, 2008, 3 : 187 - 196

← 1 2 3 4 5 →